Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Mebufotenin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GH Research Reports Phase 2B Results For Mebufotenin In JAMA
    GH Research Reports Phase 2B Results For Mebufotenin In JAMA

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262385/0/en/GH-Research-Announces-Publication-of-Phase-2b-Results-for-Mebufotenin-GH001-in-JAMA-Psychiatry-and-Reports-New-Finding-of-Severity-Independent-Efficacy-in-TRD.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    Atai, Beckley Psytech Show Positive Phase 2a Results For Bpl-003
    Atai, Beckley Psytech Show Positive Phase 2a Results For Bpl-003

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3154533/0/en/atai-Life-Sciences-and-Beckley-Psytech-Report-Positive-Phase-2a-Data-Demonstrating-Improved-Outcomes-with-a-Two-Dose-Induction-Regimen-of-BPL-003-in-Patients-with-Treatment-Resista.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD
    GH Research Meets Primary Endpoint in Ph 2b Trial with GH001 in TRD

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019385/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Phase-2b-Trial-with-GH001-in-TRD-Demonstrating-15-5-Point-Placebo-adjusted-MADRS-Reduction.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Beckley Psytech begins Phase IIa treatment resistant depression trial
    Beckley Psytech begins Phase IIa treatment resistant depression trial

    22 Dec 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/beckley-psytech-depression-trial/

    CLINICALTRIALSARENA
    22 Dec 2022
    Share Share
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003
    Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003

    21 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221221005221/en

    BUSINESSWIRE
    21 Dec 2022
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.